Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).

The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.

The invention belongs to the field of biological medicine, in particular refers to an alhydrogel-sodium chloride compound immunologic adjuvant, preparation method and use thereof. The technical problem to be solved by the invention is to provide a well-behaved and novel immunologic adjuvant. The technical solution for solving the technical problem of the invention is to provide the use of sodium chloride in preparing immunologic adjuvant and the alhydrogel-sodium chloride compound immunologic adjuvant obtained on the basis thereof. The compound immunologic adjuvant mainly includes alhydrogel and sodium chloride. The alhydrogel-sodium chloride compound immunologic adjuvant of the invention is an excellent compound immunologic adjuvant, which can be used for various antigens, and provides a new and effective choice for the development and application of vaccines due to the advantages of simple and convenient use, low cost, strong immune activity, high clinical safety and the like.

This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.

The present invention pertains to immunology, biomedicine field, specifically relates to a method for prevention or treatment of one or more of diseases relevant to the protein in the protein-cell conjugate, malignant tumors, infectious diseases caused by pathogenic microorganisms and autoimmune diseases. The method includes a step of administering to a subject in such need a prophylactically or therapeutically effective amount of a protein-cell conjugate, the said protein-cell conjugate is a conjugate formed by covalently linking a protein and a cell to a linker, respectively; the cell has free sulfhydryl groups distributed on its surface, when the cell is not linked to the linker; the linker is derived from a bifunctional cross-linking agent, and the bifunctional cross-linking agent comprises both a group capable of reacting with an amino group and a group capable of reacting with a sulfhydryl group.

The present disclosure includes a compound of formula (1):

##STR00001## wherein cancer antigen peptide A is an MHC class I-restricted peptide consisting of 7 to 30 amino acid residues and containing at least one cysteine residue, wherein the cysteine residue of the cancer antigen peptide A binds to R.sup.1 via a disulfide bond; and R.sup.1 is hydrogen, a group of formula (2), the group of formula (3), or cancer antigen peptide D, wherein the group of formula 2 is

##STR00002## wherein X.sup.a and Y.sup.d independently represent a single bond or a divalent peptide group consisting of 1 to 4 amino acid residues, provided that the sum of the number of amino acid residues in X.sup.a and Y.sup.a is an integer of 0 to 4, and the cancer antigen peptide B is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues, wherein the amino group of the N-terminal amino acid of the cancer antigen peptide B binds to Y.sup.a in the formula (2), and the carbonyl group of the C-terminal amino acid of the cancer antigen peptide B binds to the hydroxyl group in the formula (2), and the formula (1) and the formula (2) binds via a disulfide bond, the group of formula (3) is

##STR00003## wherein X.sup.b and Y.sup.b independently represent a single bond or a divalent peptide group consisting of 1 to 4 amino acid residues, provided that the sum of the number of amino acid residues in X.sup.b and Y.sup.b is an integer of 0 to 4, and the cancer antigen peptide C is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues, wherein the carbonyl group of the C-terminal amino acid of the cancer antigen peptide C binds to X.sup.b in the formula (3), and the amino group of the N-terminal amino acid of the cancer antigen peptide C binds to the hydrogen atom in the formula (3), and the formula (1) and the formula (3) binds via a disulfide bond, and the cancer antigen peptide D is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues and containing at least one cysteine, wherein the cysteine residue of the cancer antigen peptide D binds to R.sup.1 via a disulfide bond; or a pharmaceutically acceptable salt thereof.

Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

Vaccines and methods are for immunization against Coxiella burnetii infections and Q fever. The vaccine can be for protection against a Coxiella burnetii infection, or treating or preventing at least one symptom of Q fever. The vaccine includes a delipidated C. burnetii polysaccharide derived from a cell wall lipopolysaccharide of C. burnetii. The vaccine can also be a conjugate vaccine for protection against a Coxiella burnetii infection, or treating or preventing at least one symptom of Q fever. The conjugate vaccine includes a delipidated C. burnetii polysaccharide derived from a cell wall lipopolysaccharide of C. burnetii linked to an immunogenic carrier.